https://oxurion.com/ 2026-06-03T17:22:14.619Z weekly 1 https://oxurion.com/company 2026-06-03T17:22:14.619Z monthly 0.8 https://oxurion.com/axiodis 2026-06-03T17:22:14.619Z monthly 0.9 https://oxurion.com/exagis 2026-06-03T17:22:14.619Z monthly 0.8 https://oxurion.com/blog 2026-06-03T17:22:14.619Z weekly 0.7 https://oxurion.com/contact 2026-06-03T17:22:14.619Z monthly 0.6 https://oxurion.com/investors 2026-06-03T17:22:14.619Z weekly 0.85 https://oxurion.com/investors/news 2026-06-03T17:22:14.619Z daily 0.85 https://oxurion.com/investors/corporate-governance 2026-06-03T17:22:14.619Z monthly 0.6 https://oxurion.com/investors/events 2026-06-03T17:22:14.619Z monthly 0.65 https://oxurion.com/investors/investors-contact 2026-06-03T17:22:14.619Z monthly 0.55 https://oxurion.com/investors/shareholder-information 2026-06-03T17:22:14.619Z monthly 0.7 https://oxurion.com/investors/shareholder-information/stock-quote-chart 2026-06-03T17:22:14.619Z daily 0.65 https://oxurion.com/investors/shareholder-information/financial-filings 2026-06-03T17:22:14.619Z monthly 0.7 https://oxurion.com/investors/shareholder-information/shareholder-meetings 2026-06-03T17:22:14.619Z monthly 0.6 https://oxurion.com/investors/shareholder-information/shareholder-structure-history 2026-06-03T17:22:14.619Z monthly 0.6 https://oxurion.com/investors/shareholder-information/transparency-notifications 2026-06-03T17:22:14.619Z monthly 0.6 https://oxurion.com/investors/shareholder-information/conversion-table 2026-06-03T17:22:14.619Z monthly 0.6 https://oxurion.com/investors/shareholder-information/analyst-coverage 2026-06-03T17:22:14.619Z monthly 0.55 https://oxurion.com/investors/shareholder-information/prospectus 2026-06-03T17:22:14.619Z monthly 0.6 https://oxurion.com/privacy-policy 2026-06-03T17:22:14.619Z yearly 0.3 https://oxurion.com/terms-of-use 2026-06-03T17:22:14.619Z yearly 0.3 https://oxurion.com/investors/news/oxurion-expands-its-capabilities-to-address-the-growing-demand-for-glp-1-and-peptide-clinical-research-services 2026-06-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-termination-of-discussions-for-the-french-cro-project-loi-dated-13-10-25-and-prioritization-of-the-international-target 2026-06-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2026-06-01-2026-annual-shareholders-meeting 2026-05-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2026-09-30-publication-of-the-half-year-report 2026-05-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2027-04-02-convening-of-the-annual-shareholders-meeting 2026-05-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2027-05-04-2027-annual-shareholders-meeting 2026-05-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/informatiedocument-nieuwe-aandelen-13-mei-2026 2026-05-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/new-shares-information-document-13-may-2026 2026-05-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/annual-accounts-2025 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/annual-report-2025-official-esef-version 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/annual-report-2025 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/jaarrekening-2025 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/jaarverslag-2025-officiele-esef-versie 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/jaarverslag-2025 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/annual-shareholders-meeting-june-1-2026 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/jaarlijkse-algemene-vergadering-van-aandeelhouders-1-juni-2026 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2026-04-30-convocation-ago-et-publication-du-rapport-annuel 2026-04-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/informatiedocument-nieuwe-aandelen-07-november-2025 2025-11-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/new-shares-information-document-07-november-2025 2025-11-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/interim-financial-report-half-year-results-as-of-june-30-2025 2025-09-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/tussentijdse-halfjaarresultaten-30-juni-2025 2025-09-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2025-09-30-publication-of-the-half-year-report 2025-09-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/eerste-aanvulling-op-het-prospectus-van-15-oktober-2024 2025-09-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/first-supplement-to-the-prospectus-dated-15-october-2024 2025-06-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2025-05-06-postponed-to-2025-05-13-annual-shareholders-meeting 2025-04-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2026-04-03-publication-of-the-annual-report 2025-04-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2026-05-05-annual-shareholders-meeting 2025-04-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/annual-report-2024-official-esef-version 2025-04-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/jaarverslag-2024-officiele-esef-versie 2025-04-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2025-04-11-publication-of-the-annual-report-2024 2025-04-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/annual-shareholders-meeting-may-13-2025 2025-04-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/jaarlijkse-algemene-vergadering-van-aandeelhouders-13-mei-2025 2025-04-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/new-shares-prospectus-october-15-2024 2024-10-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/noteringsprospectus-d-d-15-oktober-2024 2024-10-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/2024-half-year-report 2024-09-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-11 2026-05-29T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-19 2026-05-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-24 2026-05-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-23 2026-05-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/publication-annual-report-annual-shareholders-meeting-2 2026-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-22 2026-04-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/postponement-annual-shareholders-meeting-2 2026-04-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-signs-a-letter-of-intent-for-the-acquisition-of-an-international-cro 2026-03-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-21 2026-03-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-18 2026-03-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-extends-its-financing-program-2 2026-03-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-confirms-continuation-of-discussions-regarding-its-proposed-acquisition-of-a-french-cro 2026-02-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-20 2026-02-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-19 2026-02-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/axiodis-cro-accelerates-its-sales-and-marketing-strategy-to-support-ambitious-growth-driven-by-oxurion 2026-02-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-18 2026-01-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-17 2026-01-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-17 2026-01-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-16 2026-01-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-15 2025-12-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-secures-a-binding-e30-million-financing-facility-dedicated-to-investments-in-digital-and-crypto-assets 2025-11-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-14 2025-11-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-13 2025-11-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-ends-discussions-regarding-previously-announced-preclinical-transaction-and-continues-integration-of-a-strategic-clinical-partner 2025-11-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-12 2025-10-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-amended-transparency-notifications-from-atlas-special-opportunities-ii-llc 2025-10-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-10 2025-10-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-16 2025-10-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-provides-an-update-related-to-its-investment-strategy-in-digital-assets 2025-10-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-15 2025-10-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-11 2025-10-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-signs-letter-of-intent-for-the-contemplated-acquisition-of-a-cro-with-strong-complementarity-to-axiodis 2025-10-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/axiodis-cro-the-french-subsidiary-of-the-oxurion-group-announces-a-dual-ai-driven-strategic-initiative-to-transform-clinical-trials 2025-09-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-10 2025-09-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-publishes-first-half-2025-results 2025-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-9 2025-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-confirms-progress-in-negotiations-related-to-its-treasury-diversification-strategy-closing-of-the-transaction-expected-before-september-25-2025 2025-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-ubs-group-ag 2025-08-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-ends-rd-program-in-geographic-atrophy-and-refocuses-on-new-cro-activities 2025-08-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-8 2025-08-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-it-obtained-an-improved-indicative-e30-million-financing-offer-to-initiate-its-plan-to-diversify-by-allocating-part-of-its-treasury-into-digital-assets 2025-08-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-completes-the-acquisition-of-axiodis-cro-and-accelerates-the-structuring-of-its-european-clinical-data-platform 2025-08-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-amended-transparency-notification-from-atlas-special-opportunities-ii-llc-3 2025-07-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-14 2025-07-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-13 2025-07-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-12 2025-07-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-11 2025-07-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-9 2025-07-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-8 2025-07-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-plans-to-launch-a-treasury-diversification-strategy-into-digital-assets-under-a-e10m-indicative-agreement-with-its-main-investor 2025-07-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-7 2025-07-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-7 2025-07-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-10 2025-07-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-6 2025-07-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-secures-financing-for-the-acquisition-of-axiodis-cro-and-targets-closing-on-august-1-2025 2025-07-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-the-fulfilment-of-the-second-condition-precedent-in-the-acquisition-of-axiodis 2025-07-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-6 2025-06-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-5 2025-06-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-4 2025-06-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-amended-transparency-notification-from-atlas-special-opportunities-ii-llc-2 2025-06-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-5 2025-06-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-3 2025-06-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-9 2025-06-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-signs-a-letter-of-intent-for-the-planned-acquisition-of-a-preclinical-microbiology-cro-to-diversify-and-strengthen-its-presence-in-the-toulouse-region 2025-06-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-moves-forward-with-the-planned-acquisition-of-axiodis 2025-06-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc-2 2025-05-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-results-on-the-annual-shareholders-meeting-of-13-may-2025 2025-05-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-4 2025-05-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-3 2025-05-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc-2 2025-05-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-8 2025-05-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-the-signing-of-a-binding-agreement-to-acquire-french-biometrics-specialist-axiodis-cro 2025-05-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-that-the-transaction-of-july-2024-is-stopped-and-confirms-continuation-of-discussions-regarding-the-acquisition-project-announced-in-march-2025 2025-04-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/publication-annual-report-annual-shareholders-meeting 2025-04-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/postponement-annual-shareholders-meeting 2025-04-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-ii-llc 2025-04-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-amended-transparency-notification-from-atlas-special-opportunities-ii-llc 2025-03-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ii-llc 2025-03-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-7 2025-03-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc-4 2025-03-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-signs-a-letter-of-intent-for-the-planned-acquisition-of-a-biometrics-focused-cro 2025-03-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-extends-its-financing-program 2025-03-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-strengthens-its-board-of-directors-with-the-arrival-of-nelly-souleymane 2025-02-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-12 2025-01-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-amended-transparency-notification-from-atlas-special-opportunities-llc 2025-01-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-6 2025-01-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-11 2025-01-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-10 2025-01-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-9 2025-01-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-5 2025-01-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-postponement-of-signing-for-strategic-transaction-due-to-ongoing-discussions 2024-12-31T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/french-authorities-approve-oxurions-strategic-transaction-under-specific-conditions 2024-12-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-8 2024-12-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc-3 2024-12-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-4 2024-12-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-7 2024-12-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-6 2024-12-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-5 2024-11-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-terminates-its-private-judicial-reorganizationprocedure-following-amicable-settlement-agreements 2024-11-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-that-its-potential-acquisition-is-subject-to-foreign-investment-control 2024-11-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-nv-key-developments-and-timeline-for-current-the-potential-acquisition 2024-10-29T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-4 2024-10-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-3 2024-10-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-3 2024-10-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc-2 2024-10-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2024-10-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas-2 2024-09-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc-2 2024-09-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-09-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-the-reverse-share-split 2024-09-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-the-opening-of-a-private-judicial-reorganization-procedure 2024-09-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-received-transparency-notification-from-atlas-special-opportunities-llc 2024-09-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-publishes-first-half-2024-results 2024-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/progress-in-the-fight-against-amd 2024-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-date-of-consolidation-of-shares-and-last-day-of-trading-of-current-shares 2024-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-share-consolidation 2024-07-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-results-on-the-extraordinary-general-meeting-egm-of-24-july-2024 2024-07-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2024-07-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0297july-18-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-07-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0296july-11-2024oxurion-provides-clarification-on-the-agenda-of-the-extraordinary-general-shareholders-meeting-to-be-held-on-24-july-2024 2024-07-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0295july-8-2024oxurion-signs-a-letter-of-intent-and-enters-into-exclusive-negotiations-to-potentially-acquire-a-pioneering-french-cro-in-stem-cell-production 2024-07-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0294july-4-2024oxurion-announces-the-results-of-the-extraordinary-general-meeting-egm-held-on-4-july-2024-and-convenes-a-new-egm-on-24-july-2024 2024-07-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0259june-7-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-06-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0260june-4-2024oxurion-announces-extraordinary-general-shareholders-meeting 2024-06-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0261may-27-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-05-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0262may-23-2024oxurion-announces-results-on-the-annual-shareholders-meeting-of-16-may-2024 2024-05-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0263may-23-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2024-05-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0264may-16-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-05-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0265may-14-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2024-05-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0266may-13-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-05-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0267may-6-2024important-advances-in-oxurions-rd-program-on-geographic-atrophy-secondary-to-amd 2024-05-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0268april-25-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-04-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0269april-15-2024publication-annual-report-annual-shareholders-meeting 2024-04-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0270april-11-2024oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2024-04-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0271april-10-2024oxurion-receives-eur-450000-in-the-framework-of-the-atlas-funding-program-eleventh-tranche-fully-issued-and-paid-up 2024-04-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0272april-5-2024postponement-annual-shareholders-meeting-amendment-financial-calendar 2024-04-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0273march-28-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-03-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0274march-27-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-atlas-amended-version 2024-03-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0275march-26-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-atlas-erroneous-version 2024-03-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0276march-25-2024oxurion-announces-its-presence-at-the-paris-smallcap-event-on-march-28-2024 2024-03-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0277march-22-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-03-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0278march-21-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-atlas 2024-03-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0279march-13-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-03-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0280march-7-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-03-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0281march-5-2024oxurion-receives-eur-300000-in-the-framework-of-the-atlas-funding-program-tenth-tranche-fully-issued-and-paid-up 2024-03-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0282march-4-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-atlas 2024-03-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0283february-29-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-02-29T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0284february-23-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-02-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0285february-15-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-atlas 2024-02-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0286february-14-2024oxurion-receives-eur-850000-in-the-framework-of-the-atlas-funding-program-eight-and-ninth-tranches-fully-issued-and-paid-up 2024-02-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0287february-9-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-02-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0288february-7-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-atlas 2024-02-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0289february-5-2024highlight-on-the-new-strategic-and-financial-plans 2024-02-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0290january-22-2024oxurion-announces-new-strategic-orientation-to-de-risk-and-diversify 2024-01-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0291january-19-2024information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-atlas 2024-01-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0292january-17-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-01-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0293january-12-2024oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2024-01-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0167december-28-2023oxurion-avoids-bankruptcy-announces-board-and-management-changes-and-enters-into-binding-letter-of-intent-with-its-main-creditor-atlas 2023-12-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0116december-6-2023oxurion-receives-transparency-notification-from-negma-group 2023-12-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0168december-1-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-12-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0169november-20-2023oxurion-discloses-topline-data-from-kalahari-phase-2-part-b-trial-of-novel-pkal-inhibitor-thr-149-in-diabetic-macular-edema 2023-11-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0170november-19-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-11-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0171november-16-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-11-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0172november-16-2023oxurion-receives-eur-1-0-million-under-amended-atlas-funding-program-total-of-eur-3-5-million-in-unconditional-funding-allowing-company-to-reach-topline-data-from-kalahari-t 2023-11-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0173november-15-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-11-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0174november-6-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-11-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0175november-3-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-11-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0176october-30-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-10-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0177october-25-2023oxurion-receives-eur-1-5-million-under-amended-atlas-funding-program-total-of-eur-3-5-million-in-unconditional-funding-allowing-company-to-achieve-topline-data-from-kalahari-t 2023-10-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0178october-20-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-10-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0179october-20-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-10-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0180october-10-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-10-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0181october-3-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-10-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0182september-29-2023oxurion-publishes-first-half-2023-results 2023-09-29T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0183september-27-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-09-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0184september-18-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-09-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0185september-18-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-09-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0186september-18-2023oxurion-receives-first-eur-1-million-under-amended-atlas-funding-program 2023-09-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0187september-11-2023oxurion-announces-key-amendments-to-atlas-and-kreos-pontifax-agreements-enabling-kalahari-trial-to-progress-to-topline-results-in-2023 2023-09-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0188september-7-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-09-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0189september-1-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0190september-1-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0191august-25-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-08-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0192august-23-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-08-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0193august-23-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-08-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0194august-21-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-08-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0195august-21-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-08-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0196august-16-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-08-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0197august-11-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-08-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0198august-11-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-08-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0199august-11-2023oxurion-receives-funding-of-eur-one-million-under-atlas-special-opportunities-llc-atlas-funding-program 2023-08-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0200august-7-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-08-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0201august-7-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-08-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0202august-4-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-08-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0203august-4-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-08-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0204july-26-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-07-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0205july-26-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-ll 2023-07-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0206july-25-2023oxurion-receives-upfront-payment-of-400000-following-oncurious-asset-license-by-vib 2023-07-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0207july-14-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-07-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0208july-6-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-07-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0209july-6-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-07-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0210july-5-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-07-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0211july-3-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-07-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0212june-28-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-06-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0213june-23-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-06-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0214june-22-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-06-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0215june-16-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-06-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0216june-15-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-06-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0217june-15-2023oxurion-issues-eur-1-0-million-in-bonds-for-tranche-3-of-the-funding-program-with-atlas-special-opportunities-llc 2023-06-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0218june-12-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-06-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0219june-12-2023oxurion-finalizes-enrollment-in-kalahari-phase-2-part-b-trial-of-novel-pkal-inhibitor-thr-149-in-diabetic-macular-edema 2023-06-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0220june-9-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-06-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0221june-6-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-06-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0222june-5-2023oxurion-announces-results-of-the-extraordinary-shareholders-meeting-of-22-may-2023 2023-06-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0223june-1-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-06-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0224june-1-2023oxurion-to-participate-in-upcoming-conferences 2023-06-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0225may-31-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-05-31T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0226may-26-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-05-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0227may-25-2023oxurion-reaches-enrollment-target-in-kalahari-phase-2-part-b-trial-of-novel-pkal-inhibitor-thr-149-in-diabetic-macular-edema 2023-05-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0228may-22-2023oxurion-issues-eur-2-0-million-in-bonds-for-tranche-2-of-the-funding-program-with-atlas-special-opportunities-llc 2023-05-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0229may-19-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-05-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0230may-15-2023oxurion-announces-results-of-the-annual-shareholders-meeting-of-2-may-2023 2023-05-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0231may-12-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-05-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0232may-12-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-05-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0233may-5-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-05-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0234may-3-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-05-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0235april-28-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-04-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0236april-27-2023oxurion-issues-eur-2-0-million-in-bonds-for-tranche-1-b-of-the-funding-program-with-atlas-special-opportunities-llc 2023-04-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0237april-24-2023oxurion-receives-transparency-notifications-from-atlas-special-opportunities-llc 2023-04-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0238april-14-2023oxurion-receives-transparency-notification-from-atlas-special-opportunities-llc 2023-04-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0239april-7-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-04-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0240march-31-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-03-31T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0241march-31-2023oxurion-publishes-2022-annual-report 2023-03-31T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0242march-24-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-atlas 2023-03-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0243march-20-2023oxurion-issues-eur-2-8-million-in-bonds-for-tranche-1-a-of-funding-program-with-atlas-special-opportunities-ll 2023-03-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0244march-14-2023oxurion-provides-update-on-recruitment-for-kalahari-phase-2-part-b-trial-of-novel-pkal-inhibitor-thr-149-in-diabetic-macular-edema-and-announces-board-changes 2023-03-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0245march-9-2023oxurion-receives-transparency-notification-from-negma-group 2023-03-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0246march-2-2023oxurion-receives-transparency-notification-from-negma-group 2023-03-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0247march-2-2023oxurion-announces-subscription-agreement-with-atlas-providing-the-company-with-up-to-e20-million-in-funding 2023-03-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0248march-2-2023funding-program-between-oxurion-and-negma-ends 2023-03-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0249february-24-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2023-02-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0250february-24-2023oxurion-receives-transparency-notifications-from-negma-group 2023-02-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0251february-17-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2023-02-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0252february-17-2023oxurion-receives-transparency-notifications-from-negma-group 2023-02-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0253february-10-2023oxurion-receives-transparency-notifications 2023-02-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0254february-10-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2023-02-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0255february-3-2023oxurion-receives-transparency-notifications-from-negma-group 2023-02-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0256january-27-2023information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2023-01-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0257january-27-2023oxurion-provides-further-details-concerning-the-second-amendment-to-negma-funding-program 2023-01-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0258january-25-2023oxurion-announces-second-amendment-to-negma-funding-program 2023-01-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0108december-21-2022oxurion-receives-transparency-notification-from-negma-group 2022-12-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0109december-21-2022oxurion-receives-transparency-notifications-from-negma-group 2022-12-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0110december-19-2022oxurion-receives-transparency-notifications-from-negma-group 2022-12-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0111december-14-2022oxurion-announces-the-continuation-of-kalahari-phase-2-part-b-study-in-diabetic-macular-edema-following-interim-analysis 2022-12-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0112december-13-2022oxurion-receives-transparency-notifications-from-negma-group 2022-12-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0113december-12-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-12-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0114december-7-2022oxurion-receives-transparency-notifications-from-negma-group 2022-12-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0115december-6-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-12-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0117december-2-2022oxurion-receives-transparency-notifications-from-negma-group 2022-12-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0118december-2-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-12-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0119november-28-2022oxurion-receives-transparency-notifications-from-negma-group 2022-11-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0120november-25-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-11-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0121november-23-2022oxurion-further-improves-thr-149-patent-position 2022-11-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0122november-18-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-11-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0123november-18-2022oxurion-announces-interim-analysis-for-kalahari-trial 2022-11-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0124november-17-2022oxurion-receives-transparency-notifications-based-on-new-denominator 2022-11-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0125november-11-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-11-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0126november-4-2022oxurion-receives-transparency-notification-from-fidelity-management-research-company-llc 2022-11-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0127november-4-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-11-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0128october-28-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-10-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0129october-18-2022oxurion-to-participate-in-upcoming-investor-conferences 2022-10-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0130september-30-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-09-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0131september-12-2022oxurion-to-participate-in-upcoming-scientific-and-investor-conferences 2022-09-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0132september-7-2022oxurion-publishes-first-half-2022-results 2022-09-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0133september-2-2022oxurion-announces-amendment-to-funding-program-with-negma-group-for-eur-6-million-in-funding 2022-09-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0134august-26-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-08-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0135august-24-2022oxurion-to-present-at-upcoming-scientific-and-investor-conferences 2022-08-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0136july-29-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-07-29T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0137july-11-2022oxurion-announces-presentations-at-upcoming-scientific-and-investor-conferences 2022-07-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0138june-30-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-of-negma-convertible-bonds-and-partial-reimbursement-of-kreos-pontifax-convertible-bonds 2022-06-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0139june-13-2022oxurion-announces-two-presentations-at-the-macula-society-45th-annual-meeting 2022-06-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0140june-7-2022oxurion-announces-preclinical-presentation-on-thr-149-at-kinin2022 2022-06-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0141june-3-2022oxurion-announces-two-upcoming-presentations-at-the-macula-society-45th-annual-meeting 2022-06-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0142june-1-2022oxurion-to-participate-in-upcoming-investor-conferences 2022-06-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0143may-31-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-05-31T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0144may-25-2022oxurion-announces-results-of-the-extraordinary-shareholders-meeting-held-on-24-may-2022 2022-05-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0145may-24-2022oxurion-announces-upcoming-preclinical-presentation-on-thr-149-at-kinin2022 2022-05-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0146may-9-2022oxurion-announces-top-line-results-from-part-a-of-phase-2-integral-trial-evaluating-thr-687-for-treatment-of-diabetic-macular-edema-dme 2022-05-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0147may-6-2022oxurion-announces-results-of-the-extraordinary-and-annual-shareholders-meetings-of-3-may-2022-and-invitation-to-the-extraordinary-shareholders-meeting-of-24-may-20 2022-05-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0148may-5-2022oxurion-to-participate-in-upcoming-conferences 2022-05-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0149may-3-2022oxurion-announces-preclinical-data-on-thr-687-for-the-treatment-of-diabetic-macular-edema-at-the-2022-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting 2022-05-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0150april-29-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notice-from-negma 2022-04-29T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0151april-11-2022oxurion-announces-upcoming-preclinical-data-presentation-on-thr-687-for-the-treatment-of-diabetic-macular-edema-at-the-2022-association-for-research-in-vision-and-ophthalmology 2022-04-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0152april-1-2022oxurion-announces-extraordinary-and-annual-shareholders-meetings 2022-04-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0153march-30-2022information-on-the-total-number-of-voting-rights-denominator-following-eur-10-million-private-placement-and-conversion-notice-from-negma 2022-03-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0154march-28-2022oxurion-to-participate-in-needham-virtual-healthcare-conference 2022-03-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0155march-25-2022oxurion-publishes-2021-annual-report 2022-03-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0156march-17-2022oxurion-receives-transparency-notifications-from-fidelity-management-research-company-llc-and-novartis-pharma-ag 2022-03-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0157march-7-2022oxurion-successfully-closes-eur-10-million-in-private-placement 2022-03-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0158march-3-2022oxurion-succesfully-raises-eur-10-million-from-leading-us-and-european-healthcare-investors-in-a-private-equity-placement 2022-03-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0159february-22-2022information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-negma 2022-02-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0160february-22-2022oxurion-nv-announces-2021-full-year-results-and-2022-outlook 2022-02-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0161february-14-2022oxurion-announces-new-data-on-thr-149-phase-2-clinical-trial-kalahari-in-dme-at-the-angiogenesis-exudation-and-degeneration-2022-conference 2022-02-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0162february-11-2022oxurion-announces-upcoming-presentation-on-thr-149-phase-2-clinical-trial-kalahari-at-the-angiogenesis-exudation-and-degeneration-2022-conference 2022-02-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0163february-8-2022oxurion-to-participate-in-the-2022-bio-ceo-and-investor-conference 2022-02-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0164january-18-2022oxurion-to-participate-in-the-10th-edition-of-degroof-petercams-healthcare-conference 2022-01-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0165january-7-2022oxurion-provides-update-on-clinical-pipeline-progress 2022-01-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0166january-4-2022oxurion-to-present-at-the-h-c-wainwright-bioconnect-2022-virtual-conference 2022-01-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0079december-30-2021information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-negma 2021-12-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0080november-30-2021information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-from-negma 2021-11-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0081november-24-2021oxurion-to-present-at-the-ophthalmology-day-at-btig 2021-11-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0082november-22-2021oxurion-nv-secures-eur-10-million-convertible-bond-financing-from-kreos-capital-and-pontifax-ventures 2021-11-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0083november-15-2021first-patient-dosed-in-part-b-of-phase-2-kalahari-study-evaluating-multiple-administrations-of-thr-149-versus-aflibercept-for-treatment-of-diabetic-macular-edema-dme 2021-11-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0084november-4-2021oxurion-nv-announces-initiation-of-equity-analyst-coverage-by-h-c-wainwright-with-a-buy-recommendation 2021-11-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0085november-3-2021information-on-the-total-number-of-voting-rights-denominator-following-conversion-notices-negma 2021-11-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0086october-13-2021oxurion-nv-announces-first-patient-dosed-in-its-phase-2-study-evaluating-thr-687-for-the-treatment-of-diabetic-macular-edema-dme 2021-10-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0087october-11-2021positive-phase-2-part-a-thr-149-data-shared-at-the-america-society-of-retina-specialists-asrs-annual-scientific-meeting 2021-10-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0088october-5-2021oxurion-to-present-at-the-lytham-partners-fall-2021-investor-conference 2021-10-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0089september-30-2021oxurion-announces-positive-results-from-part-a-of-phase-2-study-evaluating-thr-149-for-treatment-of-diabetic-macular-edema-dme 2021-09-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0090september-9-2021oxurion-nv-business-financial-update-h1-2021 2021-09-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0091september-8-2021oxurion-to-present-clinical-and-pre-clinical-data-at-upcoming-euretina-2021-virtual-congress 2021-09-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0092august-17-2021oxurion-nv-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme-in-ophthalmology-science-the-american-academy-of-ophthalmology-journal 2021-08-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0093august-16-2021oxurion-nv-journal-of-pharmacokinetics-and-pharmacodynamics-highlights-desirable-pk-pd-profiles-of-thr-687-and-thr-149 2021-08-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0094august-5-2021oxurion-to-participate-in-upcoming-investor-meetings 2021-08-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0095june-25-2021oxurion-nv-to-focus-resources-on-clinical-assets-thr-687-and-thr-149 2021-06-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0096june-10-2021oxurion-confirms-institutional-review-board-approval-and-submission-of-the-investigational-new-drug-application-to-the-fda-to-start-phase-2-study-evaluating-thr-687-for-diabetic-m 2021-06-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0097june-8-2021oxurion-completes-patient-enrollment-for-part-a-of-phase-2-study-evaluating-thr-149-for-treatment-of-diabetic-macular-edema-dme 2021-06-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0098may-17-2021oxurion-nv-appoints-tom-graney-cfa-as-chief-executive-officer 2021-05-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0099april-30-2021oxurion-nv-presenting-scientific-data-at-arvo-2021-annual-meeting 2021-04-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0100april-13-2021oxurion-nv-to-present-at-wet-amd-and-dme-drug-development-summit 2021-04-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0101april-7-2021oxurion-nv-publication-in-progress-in-retinal-and-eye-research-highlights-the-potential-of-pan-rgd-integrin-antagonists-to-improve-the-treatment-of-diabetic-retinopath 2021-04-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0102april-6-2021oxurion-nv-enters-into-a-capital-commitment-of-up-to-e30-million-with-negma-group 2021-04-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0103march-31-2021oxurion-to-participate-in-upcoming-investor-meetings 2021-03-31T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0104march-17-2021oxurion-nv-business-and-financial-update-fy-2020 2021-03-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0105march-8-2021oxurion-to-participate-in-upcoming-investor-meetings 2021-03-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0106january-20-2021oxurion-nv-appoints-prof-alan-stitt-as-chief-scientific-officer 2021-01-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0107january-7-2021oxurion-to-participate-in-upcoming-investor-meetings 2021-01-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0062november-9-2020oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices 2020-11-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0063october-15-2020oxurion-nv-business-update-q3-2020 2020-10-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0064october-13-2020oxurion-nv-appoints-tom-graney-cfa-as-chief-financial-officer 2020-10-13T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0065october-8-2020invitation-oxurion-rd-investor-day-virtual-15-october-2020-at-5-30pm-cet-11-30am-et 2020-10-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0066october-5-2020save-the-date-oxurion-to-host-virtual-rd-investor-day-on-15-october-2020 2020-10-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0067september-29-2020oxurion-nv-to-present-new-pre-clinical-data-on-thr-687-at-euretina-2020-virtual-meeting-oct-2-4 2020-09-29T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0068september-17-2020oxurion-nv-business-update-h1-2020 2020-09-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0069september-14-2020oxurion-nv-to-present-at-h-c-wainwright-co-22nd-annual-global-investment-conference 2020-09-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0070september-11-2020oxurion-nv-business-update-and-first-half-2020-financial-results-to-be-announced-on-17-september 2020-09-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0071september-1-2020oxurion-nv-reports-first-patient-dosed-in-phase-2-study-evaluating-thr-149-for-treatment-of-diabetic-macular-edema-dme 2020-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0072august-3-2020oxurion-nv-appoints-grace-chang-m-d-ph-d-as-chief-medical-officer 2020-08-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0073may-7-2020oxurion-nv-business-update-q1-2020 2020-05-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0074march-28-2020oxurion-nv-covid-19-statement 2020-03-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0075march-12-2020oxurion-nv-business-update-fy-2019 2020-03-12T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0076february-9-2020oxurion-nv-expert-presentation-of-positive-topline-data-from-a-phase-1-study-evaluating-thr-687-for-the-treatment-of-dme-at-angiogenesis-exudation-and-degeneration 2020-02-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0077february-5-2020oxurion-nv-additional-topline-data-from-positive-phase-1-trial-with-thr-687-in-patients-with-diabetic-macular-edema-dme-to-be-presented-at-the-upcoming-angiogenesis 2020-02-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0078january-7-2020oxurion-nv-reports-positive-topline-data-from-phase-1-study-evaluating-thr-687-for-treatment-of-dme 2020-01-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0041december-21-2019oxurion-nv-announces-the-passing-of-dr-claude-sander-chief-legal-officer-and-corporate-secretary-to-the-board 2019-12-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0042december-19-2019oxurion-nv-to-focus-clinical-development-on-molecules-targeting-vegf-independent-pathways-for-treatment-of-dme 2019-12-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0043october-18-2019oxurion-nv-business-update-q3-2019 2019-10-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0044october-9-2019oxurion-nv-to-provide-business-and-clinical-update-at-upcoming-american-academy-of-ophthalmology-annual-meeting-aao-and-ophthalmology-innovation-summit-ois-aao-in-san-franc 2019-10-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0045september-9-2019oxurion-nv-reports-additional-positive-topline-data-from-phase-1-with-thr-149-a-novel-potent-plasma-kallikrein-inhibitor-for-dme 2019-09-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0046september-5-2019oxurion-nv-business-update-h1-2019 2019-09-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0047september-4-2019oxurion-completes-enrollment-of-phase-1-clinical-trial-evaluating-thr-687-a-novel-pan-rgd-integrin-antagonist-for-the-treatment-of-diabetic-macular-edema-dme 2019-09-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0048september-2-2019oxurion-to-make-a-late-breaker-presentation-of-topline-thr-149-plasma-kallikrein-inhibitor-phase-1-clinical-data-at-euretina-2019 2019-09-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0049august-20-2019oxurion-nv-reports-topline-month-3-results-of-phase-2a-study-evaluating-thr-317-anti-plgf-in-combination-with-ranibizumab-for-dme 2019-08-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0050july-1-2019oxurion-nv-reports-positive-topline-phase-1-results-with-thr-149-a-novel-potent-plasma-kallikrein-inhibitor-for-the-treatment-of-dme 2019-07-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0051june-11-2019oncurious-nv-receives-project-grant-from-vlaio-to-progress-its-pipeline-of-next-generation-cancer-immunotherapies 2019-06-11T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0052june-6-2019oxurion-nv-data-from-phase-1-2-clinical-study-evaluating-thr-317-anti-plgf-for-dme-presented-at-2019-floretina-meeting 2019-06-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0053may-10-2019regulated-information-transparency-statement-oxur-shares 2019-05-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0054may-10-2019regulated-information-transparency-statement-clay 2019-05-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0055may-8-2019oxurion-nv-business-update-q1-2019 2019-05-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0056april-26-2019oxurion-nv-to-present-further-preclinical-data-at-2019-arvo-meeting 2019-04-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0057april-24-2019oxurion-nv-announces-full-enrollment-in-phase-1-trial-evaluating-the-safety-of-plasma-kallikrein-inhibitor-thr-149-for-treatment-of-dme-ahead-of-schedule 2019-04-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0058april-4-2019oxurion-nv-announces-full-enrollment-of-its-phase-2-trial-evaluating-efficacy-and-safety-of-the-combination-of-anti-plgf-thr-317-and-anti-vegf-ranibizumab-for-the-treatment-of 2019-04-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0059march-7-2019oxurion-nv-business-update-fy-2018 2019-03-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0060february-28-2019oxurion-nv-to-present-preclinical-evaluation-of-plasma-kallikrein-inhibition-for-dme-at-2019-euretina-winter-meeting 2019-02-28T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0061february-4-2019oxurion-nv-to-present-at-the-2019-bio-ceo-investor-conference 2019-02-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0013december-19-2018oxurion-nv-to-present-at-2019-biotech-showcase-conference-and-participate-in-ceo-power-breakfast-roundtable-during-the-37th-annual-j-p-morgan-healthcare-conference 2018-12-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0014november-5-2018oxurion-and-beta-therapeutics-to-develop-new-heparanase-inhibitors-for-treatment-of-dry-amd 2018-11-05T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0015november-2-2018oxurion-supports-sight-saving-diabetes-programs 2018-11-02T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0016october-29-2018oxurion-nv-announces-the-appointment-of-adrienne-graves-to-its-board-of-directors 2018-10-29T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0017october-24-2018oxurion-nv-to-present-at-the-upcoming-ophthalmology-innovation-summit-and-provide-a-clinical-update-at-the-american-academy-of-ophthalmology-2018-annual-meeting 2018-10-24T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0018october-22-2018oxurion-nv-extends-partnership-with-retina-global-in-support-of-bolivian-diabetic-retinopathy-boldr-project 2018-10-22T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0019october-19-2018oxurion-nv-business-update-q3-2018 2018-10-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0020september-20-2018oxurion-nv-enrolls-first-patient-in-phase-1-clinical-trial-evaluating-thr-687-a-novel-pan-rgd-integrin-antagonist-for-treatment-of-diabetic-macular-edema-dme 2018-09-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0021september-20-2018oxurion-enrolls-first-patient-in-phase-2-clinical-study-evaluating-thr-317-anti-plgf-for-treatment-of-idiopathic-macular-telangiectasia-type-1-mactel-1 2018-09-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0022september-17-2018oxurion-nv-to-present-further-scientific-findings-supporting-therapeutic-potential-of-thr-317-and-thr-687-as-promising-new-therapies-for-diabetic-eye-disease-at-upcoming-eure 2018-09-17T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0023september-10-2018oxurion-nv-announces-new-euronext-brussels-stock-ticker-oxur-and-launch-of-new-website 2018-09-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0024september-6-2018thrombogenics-business-update-h1-2018 2018-09-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0025september-3-2018thrombogenics-becomes-oxurion 2018-09-03T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0026july-27-2018regulated-information-transparency-statement 2018-07-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0027july-19-2018thrombogenics-reports-day-150-topline-data-from-its-phase-1-2-clinical-study-evaluating-thr-317-anti-plgf-for-the-treatment-of-diabetic-macular-edema-dme 2018-07-19T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0028june-27-2018thrombogenics-plans-name-change-to-oxurion 2018-06-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0029june-21-2018thrombogenics-partners-with-prevent-blindness-at-2018-focus-on-eye-health-national-summit-in-washington-dc 2018-06-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0030may-25-2018thrombogenics-enrolls-first-patient-in-phase-1-clinical-study-evaluating-thr-149-a-plasma-kallikrein-inhibitor-for-treatment-of-diabetic-macular-edema-dme 2018-05-25T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0031may-23-2018thrombogenics-to-present-a-preclinical-overview-of-its-two-most-advanced-diabetic-eye-disease-clinical-candidates-thr-317-and-thr-149-at-easdec-2018 2018-05-23T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0032may-14-2018thrombogenics-presenting-industry-expertise-and-developments-at-bioequity-europe-and-knowledge-for-growth-meetings-in-ghent-belgium 2018-05-14T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0033may-9-2018thrombogenics-business-update-q1-2018 2018-05-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0034april-27-2018regulated-information-transparency-statement 2018-04-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0035april-27-2018thrombogenics-initiates-phase-2-clinical-study-evaluating-anti-plgf-thr-317-in-combo-with-anti-vegf-ranibizumab-for-treatment-of-dme 2018-04-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0036april-6-2018thrombogenics-announces-publication-in-the-journal-of-medicinal-chemistry-of-preclinical-data-supporting-therapeutic-potential-of-thr-149 2018-04-06T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0037april-4-2018thrombogenics-reports-initial-data-from-its-clinical-study-evaluating-thr-317-for-the-treatment-of-diabetic-macular-edema-dme 2018-04-04T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0038march-15-2018thrombogenics-business-update-fy-2017 2018-03-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0039january-30-2018disclosure-in-accordance-with-belgian-law-of-2-may-2007 2018-01-30T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0040january-26-2018novartis-pharma-ag-holding-5-69-of-thrombogenics-equity-capital 2018-01-26T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0001december-8-2017thrombogenics-patient-enrolment-in-phase-ii-circle-study-evaluating-thr-409-ocriplasmin-for-non-proliferative-diabetic-retinopathy-discontinued-due-to-slow-recruitment-rate 2017-12-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0002november-8-2017thrombogenics-strengthens-leadership-team 2017-11-08T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0003october-20-2017thrombogenics-business-update-q3-2017 2017-10-20T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0004october-9-2017thrombogenics-announces-publication-in-experimental-eye-research-of-preclinical-data-supporting-therapeutic-potential-of-thr-317-in-dr 2017-10-09T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0005september-27-2017thrombogenics-presenting-thr-687-preclinical-data-at-european-association-for-vision-and-eye-research-ever-meeting 2017-09-27T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0006september-21-2017thrombogenics-provides-business-and-clinical-update-at-european-and-us-investor-meetings 2017-09-21T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0007september-18-2017thrombogenics-regains-global-rights-to-jetrea-ocriplasmin 2017-09-18T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0008september-7-2017thrombogenics-business-update-h1-2017 2017-09-07T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0009september-1-2017oncurious-nv-acquires-unique-portfolio-of-next-generation-immuno-oncology-assets-from-vib 2017-09-01T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0010august-16-2017new-ocriplasmin-clinical-and-health-economic-data-presented-at-asrs-2017-in-boston 2017-08-16T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0011july-10-2017thrombogenics-and-bioinvent-amending-long-standing-monoclonal-antibody-development-agreement 2017-07-10T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/news0012june-15-2017thomas-clay-appointed-chairman-of-the-board-of-directors 2017-06-15T00:00:00.000Z yearly 0.5 https://oxurion.com/investors/news/oxurion-announces-the-temporary-suspension-of-the-financing-programme-dedicated-to-investments-in-digital-assets-and-crypto-assets 2026-01-19T00:00:00.000Z yearly 0.5